The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

18 articles for R White


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
36
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.EBI
Merck Research Laboratories
20
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.EBI
Bristol Myers Squibb
24
Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase.EBI
Merck Research Laboratories
14
Structure-Based Design of Potent and Selective CK1¿ Inhibitors.EBI
TBA
11
Epibatidine isomers and analogues: structure-activity relationships.EBI
University of Leicester
22
Design, synthesis and in vitro evaluation of novel bivalent S-adenosylmethionine analogues.EBI
University of Leeds
22
Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.EBI
Salk Institute
6
Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers.EBI
Procter & Gamble Pharmaceuticals
41
Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.EBI
Merck Research Laboratories
2
Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.EBI
Procter & Gamble Pharmaceuticals
274
PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereofBDB
Epizyme
47
Heterocyclic derivatives and their use in the treatment of neurological disordersBDB
Novartis
179
Heterocyclic derivative and pharmaceutical composition comprising the sameBDB
Shionogi
5
Synthesis of Novel Hybrids Inspired from Bromopyrrole Alkaloids Inhibiting MMP-2 and -12 as Antineoplastic Agents.BDB
University of Kwazulu-Nata
6
3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereofBDB
Targacept
20
Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY.BDB
Synaptic Pharmaceutical
11
Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.BDB
University of California